KRAS and neoplasm: In this work, we found that the genetic dynamics of mCRC is clinically relevant since patients bearing divergent mutational evolution have a prognosis consistent with the results of liquid biopsy: in fact, patients bearing mutKRAS at liquid biopsy from a wtKRAS in primary tumor have both poorer survival and responsiveness to chemotherapy similar to KRAS mutated CRCs.